Innovations in Imaging, such as AI-Enhanced Retinal & Fundus Camera Systems are Booming Along with Revenue Opportunities Jun 4, 2025 08:45AM
Biomea Fusion, Inc. (BMEA) Forms Global Scientific Advisory Board with 22 Diabetes Experts Oct 1, 2024 09:03AM
Biomea Announces Formation of Global Scientific Advisory Board with 22 World-Renowned Diabetes Experts Oct 1, 2024 09:00AM
Biomea Fusion, Inc. (BMEA): FDA Lifts Clinical Hold on BMF-219 in Type 2 and Type 1 Diabetes Trials (Earlier) Sep 27, 2024 09:07AM
FDA Lifts Clinical Hold on BMF-219 in Type 2 and Type 1 Diabetes Trials Sep 26, 2024 02:00PM
View Older Stories

Aug 1, 2024 04:05PM Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
Jul 31, 2024 04:05PM Biomea Fusion Reports Second Quarter 2024 Financial Results and Corporate Highlights
Jul 3, 2024 03:18PM ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Biomea Fusion, Inc. Investors to Inquire About Securities Class Action Investigation – BMEA
Jun 17, 2024 09:00AM Acute Myeloid Leukemia is on the Rise as Biotechs Race to Develop Groundbreaking Therapies
Jun 16, 2024 03:56PM BMEA ANNOUNCEMENT: If You Have Suffered Losses in Biomea Fusion, Inc. (NASDAQ: BMEA), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
Jun 6, 2024 04:06PM Biomea Fusion (BMEA) Announces Clinical Hold on Trial of BMF-219 in Diabetes
Jun 6, 2024 04:05PM Biomea Fusion Announces BMF-219 in Diabetes Placed on Clinical Hold
Jun 6, 2024 04:05PM Biomea Fusion Announces BMF-219 in Diabetes Placed on Clinical Hold
Jun 3, 2024 04:05PM Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
May 30, 2024 09:12AM Biomea Fusion Announces Completion of Enrollment of First 3 Arms in Phase 2 Expansion Cohorts of COVALENT-111 Study for BMF-219 in Type 2 Diabetes
May 2, 2024 04:05PM Biomea Fusion Reports First Quarter 2024 Financial Results and Corporate Highlights
May 1, 2024 04:10PM Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Apr 1, 2024 04:10PM Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Apr 1, 2024 09:02AM Biomea Fusion Highlights Initial Data from the First Two Type 1 Diabetes Patients Dosed with BMF-219
Apr 1, 2024 09:00AM Biomea Fusion Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights
Mar 6, 2024 05:56AM Biomea Fusion (BMEA) Presents Patient Cohorts in COVALENT-111
Mar 6, 2024 03:04AM Biomea Fusion Presents Patient Cohorts in COVALENT-111 Displaying a Durable Placebo-Adjusted Mean Reduction of up to 1.4% in HbA1c While Off Therapy at Week-26, after BMF-219’s 28-Day Treatment Cycl
Mar 1, 2024 04:16PM Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Jan 9, 2024 11:04AM Biomea Fusion (BMEA) Highlights Recent Updates and Anticipated 2024 Corporate Milestones at 42nd Annual J.P. Morgan Healthcare Conference
Jan 9, 2024 11:02AM Biomea Fusion Highlights Recent Updates and Anticipated 2024 Corporate Milestones at 42nd Annual J.P. Morgan Healthcare Conference
Jan 8, 2024 09:00AM Biomea Fusion Announces Dosing of First Type 1 Diabetes Patient in Phase II Study (COVALENT-112) with BMF-219
Jan 2, 2024 04:05PM Biomea Fusion to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Dec 11, 2023 03:58AM Biomea Fusion (BMEA) Announces Near Doubling the Percentage of Patients with Durable HbA1c Reduction in the 200 mg Dose Cohorts
Dec 9, 2023 05:30PM Biomea Fusion Announces Near Doubling the Percentage of Patients with Durable HbA1c Reduction in the 200 mg Dose Cohorts
Dec 8, 2023 09:00AM Biomea Fusion Presents Long-Term Follow-Up Data Showing Improved Glycemic Control after 22 Weeks Off Treatment in Ongoing Phase II Study (COVALENT-111) of BMF-219 in Adults with Type 2 Diabetes in a P
Dec 8, 2023 09:00AM Biomea Fusion Presents Long-Term Follow-Up Data Showing Improved Glycemic Control after 22 Weeks Off Treatment in Ongoing Phase II Study (COVALENT-111) of BMF-219 in Adults with Type 2 Diabetes in a P
Dec 7, 2023 09:16AM Biomea Fusion(BMEA) to Present Long-Term Follow-Up Data from Ongoing Phase II Study of BMF-219 in Adults with Type 2 Diabetes and Results from Ex-Vivo Human Islet Experiments
Dec 7, 2023 09:15AM Biomea Fusion to Present Long-Term Follow-Up Data from Ongoing Phase II Study (COVALENT-111) of BMF-219 in Adults with Type 2 Diabetes and Results from Ex-Vivo Human Islet Experiments at the World Con
Dec 7, 2023 09:15AM Biomea Fusion to Present Long-Term Follow-Up Data from Ongoing Phase II Study (COVALENT-111) of BMF-219 in Adults with Type 2 Diabetes and Results from Ex-Vivo Human Islet Experiments at the World Con
Dec 5, 2023 08:30AM Biomea Fusion Announces Health Canada Clearance of Clinical Trial Application (CTA) for BMF-219 in Type 1 Diabetes
Nov 27, 2023 08:30AM Biomea Fusion Announces Acceptance of Three Abstracts for its Novel Menin Inhibitor Highlighting Durable Glycemic Control in Diabetes Patients at the International Conference on Advanced Technologies
Nov 27, 2023 08:30AM Biomea Fusion Announces Acceptance of Three Abstracts for its Novel Menin Inhibitor Highlighting Durable Glycemic Control in Diabetes Patients at the International Conference on Advanced Technologies
Nov 16, 2023 08:30AM Biomea Fusion Abstract “BMF-219: A Novel Therapeutic Agent to Reestablish Functional Beta Cells and Provide Long-term Glycemic Control" Selected as One of Six Oral Presentations at 21st World Congre
Nov 16, 2023 08:30AM Biomea Fusion Abstract “BMF-219: A Novel Therapeutic Agent to Reestablish Functional Beta Cells and Provide Long-term Glycemic Control" Selected as One of Six Oral Presentations at 21st World C
Nov 8, 2023 04:05PM Biomea Fusion to Present New Data from Ongoing Phase II Study (COVALENT-111) of BMF-219 in Patients with Type 2 Diabetes at the World Congress Insulin Resistance, Diabetes & Cardiovascular Disease (WC
Nov 8, 2023 04:05PM Biomea Fusion to Present New Data from Ongoing Phase II Study (COVALENT-111) of BMF-219 in Patients with Type 2 Diabetes at the World Congress Insulin Resistance, Diabetes & Cardiovascular Disease
Nov 2, 2023 09:05AM Biomea Fusion Announces Two Poster Presentations at Upcoming ASH Annual Meeting 2023
Oct 30, 2023 04:01PM Biomea Fusion Reports Third Quarter 2023 Financial Results and Corporate Highlights
Oct 17, 2023 08:30AM Biomea Fusion Announces First Patient Dosed with Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia in Phase I Clinical Trial (COVALENT-103)
Oct 5, 2023 08:30AM Biomea Fusion (BMEA) Announces FDA Clearance of IND Application for BMF-219 in Type 1 Diabetes
Oct 5, 2023 08:30AM Biomea Fusion Announces FDA Clearance of Investigational New Drug (IND) Application for BMF-219 in Type 1 Diabetes
Sep 28, 2023 08:33AM Biomea Fusion (BMEA) Announces FDA and Health Canada Clearance of the Expansion Cohorts of the Ongoing COVALENT-111 Phase II Study
Sep 28, 2023 08:30AM Biomea Fusion Announces FDA and Health Canada Clearance of the Expansion Cohorts of the Ongoing COVALENT-111 Phase II Study
Aug 31, 2023 08:31AM Biomea Fusion, Inc. (BMEA) Appoints Juan Pablo Frías as Chief Medical Officer
Aug 31, 2023 08:30AM Biomea Fusion Announces Appointment of Juan Pablo Frías, M.D. as Chief Medical Officer
Jul 31, 2023 04:01PM Biomea Fusion Reports Second Quarter 2023 Financial Results and Corporate Highlights
Jul 24, 2023 09:02AM Biomea Fusion, Inc. (BMEA) Announces BMF-219 Induces Complete Responses in Target Acute Myeloid Leukemia (AML) Patient Population
Jul 24, 2023 09:00AM BMF-219 Induces Complete Responses in Target Acute Myeloid Leukemia (AML) Patient Population
Jun 26, 2023 06:58AM Biomea Fusion (BMEA) Presents Positive Clinical Data from Initial Cohorts of Ongoing Phase II Study of BMF-219 in Patients with Type 2 Diabetes Mellitus
Jun 23, 2023 09:54PM Biomea Fusion Presents Positive Clinical Data from the Initial Cohorts of the Ongoing Phase II Study (COVALENT-111) of BMF-219 in Patients with Type 2 Diabetes Mellitus at the American Diabetes Associ
View Older Stories